openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

12-11-2020 06:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares.

An investigation on behalf of current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fennec Pharmaceuticals Inc..

Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec Pharmaceuticals Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: FENC stocks, concerns whether certain Fennec Pharmaceuticals Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Middle District of North Carolina the plaintiff alleges that the defendants failed to disclose to investors that the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices, that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) here

News-ID: 2208142 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Fennec

Hepatoblastoma Market Growing Rapidly by - Eureka Therapeutics, Fennec Pharmaceu …
DataM Intelligence has published a new research report on "Hepatoblastoma Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hepatoblastoma-market The
Investigation announced for Long-Term Investor in shares of Fennec Pharmaceutica …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Fennec Pharmaceuticals Inc.. Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec
Deadline on April 11th coming up in Lawsuit for Investors in Fennec Pharmaceutic …
A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and there are strict and short deadlines running. Deadline: April 11, 2022. NASDAQ: FENC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S.
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged Securities Laws violations by Fennec Pharmaceuticals Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: April 11, 2022. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call
Investigation announced for Investors in shares of Fennec Pharmaceuticals Inc. ( …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Fennec Pharmaceuticals Inc. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Fennec Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders. North Carolina
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged violations of Federal Securities Laws by Fennec Pharmaceuticals Inc. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 02, 2020. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On August 11,